Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

ARS Pharmaceuticals (NASDAQ:SPRY) partners with ALK to co-promote neffy, an epinephrine nasal spray, to 9,000 pediatricians.

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

SACRAMENTO – Governor Newsom announced that individual twin-packs of CalRx®-branded over-the-counter (OTC) naloxone HCL 4 mg nasal spray are now available to all Californians at a low price of $24 per ...

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

A Utah manufacturer says the truth prevailed. But a former federal regulator believes the dismissal of the case against Xlear ...

The FDA has expanded the approval of Valtoco (diazepam nasal spray) to include treatment of seizure clusters in patients aged 2 to 5 years.

Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.